PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
ALT vs. BLNK
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between ALT and BLNK is 0.26, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.3

Performance

ALT vs. BLNK - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Altimmune, Inc. (ALT) and Blink Charging Co. (BLNK). The values are adjusted to include any dividend payments, if applicable.

-60.00%-40.00%-20.00%0.00%20.00%40.00%60.00%AugustSeptemberOctoberNovemberDecember2025
6.23%
-58.25%
ALT
BLNK

Key characteristics

Sharpe Ratio

ALT:

-0.39

BLNK:

-0.45

Sortino Ratio

ALT:

-0.04

BLNK:

-0.23

Omega Ratio

ALT:

1.00

BLNK:

0.97

Calmar Ratio

ALT:

-0.37

BLNK:

-0.39

Martin Ratio

ALT:

-0.83

BLNK:

-1.01

Ulcer Index

ALT:

43.99%

BLNK:

37.62%

Daily Std Dev

ALT:

93.75%

BLNK:

83.87%

Max Drawdown

ALT:

-99.94%

BLNK:

-97.71%

Current Drawdown

ALT:

-99.75%

BLNK:

-97.71%

Fundamentals

Market Cap

ALT:

$485.78M

BLNK:

$140.63M

EPS

ALT:

-$1.57

BLNK:

-$1.43

Total Revenue (TTM)

ALT:

$15.00K

BLNK:

$95.04M

Gross Profit (TTM)

ALT:

-$153.00K

BLNK:

-$3.56M

EBITDA (TTM)

ALT:

-$71.67M

BLNK:

-$114.41M

Returns By Period

In the year-to-date period, ALT achieves a -5.27% return, which is significantly lower than BLNK's -0.00% return.


ALT

YTD

-5.27%

1M

-17.21%

6M

6.22%

1Y

-31.97%

5Y*

27.84%

10Y*

-34.23%

BLNK

YTD

-0.00%

1M

-6.71%

6M

-58.26%

1Y

-46.12%

5Y*

-8.13%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

ALT vs. BLNK — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ALT
The Risk-Adjusted Performance Rank of ALT is 2727
Overall Rank
The Sharpe Ratio Rank of ALT is 2626
Sharpe Ratio Rank
The Sortino Ratio Rank of ALT is 3131
Sortino Ratio Rank
The Omega Ratio Rank of ALT is 3131
Omega Ratio Rank
The Calmar Ratio Rank of ALT is 2424
Calmar Ratio Rank
The Martin Ratio Rank of ALT is 2727
Martin Ratio Rank

BLNK
The Risk-Adjusted Performance Rank of BLNK is 2424
Overall Rank
The Sharpe Ratio Rank of BLNK is 2323
Sharpe Ratio Rank
The Sortino Ratio Rank of BLNK is 2525
Sortino Ratio Rank
The Omega Ratio Rank of BLNK is 2626
Omega Ratio Rank
The Calmar Ratio Rank of BLNK is 2323
Calmar Ratio Rank
The Martin Ratio Rank of BLNK is 2222
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

ALT vs. BLNK - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Altimmune, Inc. (ALT) and Blink Charging Co. (BLNK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for ALT, currently valued at -0.39, compared to the broader market-2.000.002.004.00-0.39-0.45
The chart of Sortino ratio for ALT, currently valued at -0.04, compared to the broader market-4.00-2.000.002.004.006.00-0.04-0.23
The chart of Omega ratio for ALT, currently valued at 1.00, compared to the broader market0.501.001.502.001.000.97
The chart of Calmar ratio for ALT, currently valued at -0.41, compared to the broader market0.002.004.006.00-0.41-0.39
The chart of Martin ratio for ALT, currently valued at -0.83, compared to the broader market0.0010.0020.0030.00-0.83-1.01
ALT
BLNK

The current ALT Sharpe Ratio is -0.39, which is comparable to the BLNK Sharpe Ratio of -0.45. The chart below compares the historical Sharpe Ratios of ALT and BLNK, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00AugustSeptemberOctoberNovemberDecember2025
-0.39
-0.45
ALT
BLNK

Dividends

ALT vs. BLNK - Dividend Comparison

Neither ALT nor BLNK has paid dividends to shareholders.


TTM20242023202220212020201920182017
ALT
Altimmune, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%4.87%
BLNK
Blink Charging Co.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Drawdowns

ALT vs. BLNK - Drawdown Comparison

The maximum ALT drawdown since its inception was -99.94%, roughly equal to the maximum BLNK drawdown of -97.71%. Use the drawdown chart below to compare losses from any high point for ALT and BLNK. For additional features, visit the drawdowns tool.


-95.00%-90.00%-85.00%-80.00%AugustSeptemberOctoberNovemberDecember2025
-87.35%
-97.71%
ALT
BLNK

Volatility

ALT vs. BLNK - Volatility Comparison

Altimmune, Inc. (ALT) and Blink Charging Co. (BLNK) have volatilities of 18.86% and 18.95%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.


15.00%20.00%25.00%30.00%35.00%AugustSeptemberOctoberNovemberDecember2025
18.86%
18.95%
ALT
BLNK

Financials

ALT vs. BLNK - Financials Comparison

This section allows you to compare key financial metrics between Altimmune, Inc. and Blink Charging Co.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab